Bharat Biotech International Limited has signed an MoU with Gujarat Covid Vaccine Consortium (GCVC) towards contract manufacturing for the drug substance for Covaxin.

GCVC comprises of Gujarat Biotechnology Research Centre (GBRC), a Government of Gujarat undertaking, Hester Biosciences Limited and Omnibrx Biotechnologies Private Limited.

Bharat Biotech will provide the technology for the production of the drug substance for Covaxin.

GBRC will act as an advisor and mentor and will facilitate the technology transfer from Bharat Biotech. Hester shall provide the complete infrastructure at its Gujarat plant for the manufacturing of the drug substance.

Hester will be investing Rs. 40 crore for this project. This proposed manufacturing activity at Hester would not disturb any manufacturing or marketing forecasts of Hester’s on-going business, for the financial year 2021-2022.